



Attorney Docket No.: 4216.260-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Royer et al.

Confirmation No: 3928

Serial No.: 09/461,537

Group Art Unit: 1636

Filed: December 15, 1999

Examiner: M. Marvich

For: Non-Toxic, Non-Toxigenic, Non-Pathogenic Fusarium Expression System and Promoters and Terminators for Use Therein

**TERMINAL DISCLAIMER TO OBTAIN A DOUBLE
PATENTING REJECTION OVER A PENDING SECOND APPLICATION** **RECEIVED**

Commissioner for Patents
Washington, DC 20231

JUL 23 2003

Sir:

TECH CENTER 1600/2900

I am an attorney or agent of record for the instant application.


Novozymes Biotech, Inc., the owner of the entire interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second application no. **09/482,788**, filed on **13 January 2000**. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend beyond the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Please charge the required fee, estimated to be \$110.00, to Novozymes North America, Inc. Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: July 14, 2003

A handwritten signature in cursive script, reading "Robert L. Starnes", positioned above a horizontal line.

Robert L. Starnes, Ph.D.
Reg. No. 41,324
Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100



Attorney Docket No.: 4216.260-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Royer et al.

Confirmation No: 3928

Serial No.: 09/461,537

Group Art Unit: 1636

Filed: December 15, 1999

Examiner: M. Marvich

For: Non-Toxic, Non-Toxigenic, Non-Pathogenic Fusarium Expression System and Promoters and Terminators for Use Therein

TERMINAL DISCLAIMER TO OBVIATE A
DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

RECEIVED

Commissioner for Patents
Washington, DC 20231

JUL 23 2003

Sir:

TECH CENTER 1600/2900

I am an attorney or agent of record for the instant application.

Novozymes Biotech, Inc., the owner of the entire interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior **U.S. Patent Nos. 6,060,305** and **6,180,366**. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend beyond the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer.


07/22/2003 WABRHAM1 00000050 501701 09461537

03 FC:1814 110.00 DA

Please charge the required fee, estimated to be \$110.00, to Novozymes North America, Inc. Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: July 14, 2003

A handwritten signature in cursive script, reading "Robert L. Starnes", is written over a horizontal line.

Robert L. Starnes, Ph.D.
Reg. No. 41,324
Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100